- Home
- IPSC vs IFRX Comparison
IPSC vs IFRX Comparison
Compare IPSC & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- IFRX
- Stock Information
- Founded
- IPSC 2019
- IFRX 2007
- Country
- IPSC United States
- IFRX Germany
- Employees
- IPSC N/A
- IFRX N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- IFRX Health Care
- Exchange
- IPSC Nasdaq
- IFRX Nasdaq
- Market Cap
- IPSC 49.6M
- IFRX 65.8M
- IPO Year
- IPSC 2021
- IFRX 2017
- Fundamental
- Price
- IPSC $0.54
- IFRX $0.79
- Analyst Decision
- IPSC Strong Buy
- IFRX Strong Buy
- Analyst Count
- IPSC 5
- IFRX 4
- Target Price
- IPSC $3.33
- IFRX $7.75
- AVG Volume (30 Days)
- IPSC 1.2M
- IFRX 346.2K
- Earning Date
- IPSC 08-07-2025
- IFRX 08-07-2025
- Dividend Yield
- IPSC N/A
- IFRX N/A
- EPS Growth
- IPSC N/A
- IFRX N/A
- EPS
- IPSC N/A
- IFRX N/A
- Revenue
- IPSC $114,898,000.00
- IFRX $140,242.00
- Revenue This Year
- IPSC $1,064.82
- IFRX N/A
- Revenue Next Year
- IPSC N/A
- IFRX $6,309.47
- P/E Ratio
- IPSC N/A
- IFRX N/A
- Revenue Growth
- IPSC 8286.72
- IFRX 30.90
- 52 Week Low
- IPSC $0.34
- IFRX $0.71
- 52 Week High
- IPSC $3.29
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- IPSC 48.22
- IFRX 35.74
- Support Level
- IPSC $0.55
- IFRX $0.77
- Resistance Level
- IPSC $0.60
- IFRX $0.83
- Average True Range (ATR)
- IPSC 0.04
- IFRX 0.05
- MACD
- IPSC -0.00
- IFRX 0.02
- Stochastic Oscillator
- IPSC 15.96
- IFRX 35.40
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.